Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Miraculins announces private placement offering
Each unit will be comprised of one common share of the company and one half of one share purchase warrant. Each whole warrant will entitle the holder to
Each unit will be comprised of one common share of the company and one half of one share purchase warrant. Each whole warrant will entitle the holder to
The company said that the technology can be used for site-specific delivery of several drugs in a time-release fashion from combination medical devices. The patent reportedly augments and
As announced in October 2007, the FDA in the US has requested additional clinical data prior to submission of a new drug application (NDA) for TAK-475 and recommended
In a controlled clinical trial with 59 gastroesofageal reflux disease (GERD) patients treated for 14 days, the anti-secretory effect of OX17 was compared to omeprazole and famotidine. The
The laboratory will focus on the biosynthesis pathway inhibition of the major components of the fungal cell membranes to further develop the company’s intellectual properties. Another key function
The new data also showed that degarelix provided an extremely fast effect on testosterone levels, close to the immediate effect achieved with surgery (orchidectomy), the company said. The
The licensed technologies, which were co-developed by FluoroPharma and Massachusetts General Hospital (MGH) scientists, target multiple biological processes associated with Alzheimer’s disease. According to the available sources, currently,
The Sedasys System is intended for use by physician/nurse teams to administer minimal to moderate propofol sedation to patients undergoing screening and diagnostic procedures for colorectal cancer (colonoscopy),
Under the terms of the agreement, BayPoint obtains exclusive, worldwide commercial rights to certain proteomic technologies as well as clinical biomarkers that predict therapeutic response for certain ovarian
This approval allows the company’s Chinese partner, China Bao Tai, to market Microcyn Technology as a technology that provides a moist environment for wounds and accelerates wound healing